Addressing the innovation gap.
The 10 years since the mid-1990s have witnessed an unprecedented investment in Drug Discovery driven by both the unraveling of the human genome and the parallel introduction of various high-throughput technologies. During the same period, industry metrics describe a decline in the numbers of new molecular entities launched upon the global pharmaceutical markets. The Society for Medicines Research (SMR) meeting entitled "Addressing the Innovation Gap" brought together a program of expert speakers to comment upon the challenges currently facing the pharmaceutical industry and some of the measures being undertaken to enable future success.